Outcome of Biennial Screening Contrast-Enhanced Mammography (CEM) in Women With a Personal History of Breast Cancer (PHBC)
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This is a prospective clinical trial that will examine if biennial contrast-enhanced mammography added to annual 3D mammography (tomosynthesis) substantially improves breast cancer detection with minimal increase in false-positives, in women with a personal history of breast cancer.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 30
Maximum Age: 79
Healthy Volunteers: t
View:
• Asymptomatic women, ages 30-79, with a personal history of breast cancer who are at least one year out from any breast cancer surgery and/or treatment and are scheduled to have a routine annual mammogram with tomosynthesis (DBT).
Locations
United States
Pennsylvania
UPMC Magee-Womens Imaging - Bethel Park
RECRUITING
Bethel Park
UPMC Magee at the Lemieux Sports Complex
RECRUITING
Cranberry Township
Magee Womancare Monroeville
RECRUITING
Monroeville
Hillman Cancer Center at Shadyside
RECRUITING
Pittsburgh
Magee-Womens Hospital
RECRUITING
Pittsburgh
UPMC West Mifflin Outpatient Center
RECRUITING
West Mifflin
Contact Information
Primary
Wendie Berg, MD, PhD
bergwa@upmc.edu
412-641-8278
Backup
McKenna Rigling, MS
riglingmm@upmc.edu
412-641-8278
Time Frame
Start Date: 2023-11-08
Estimated Completion Date: 2031-04
Participants
Target number of participants: 1500
Treatments
Experimental: contrast-enhanced mammography
Enrolled participants will receive a baseline contrast-enhanced mammography exam for breast cancer screening, along with their scheduled 3D mammography exam, then they will receive another CEM exam for breast cancer screening at 24 months after their baseline CEM exam, and then again at 48 months. All the while, participants will still receive their annual 3D mammography exam as per their usual routine care.
Related Therapeutic Areas
Sponsors
Collaborators: Breast Cancer Research Foundation
Leads: Wendie Berg